$1.20 Earnings Per Share Expected for Ionis Pharmaceuticals Inc (NASDAQ:IONS) This Quarter
Analysts forecast that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will post earnings per share (EPS) of $1.20 for the current quarter, Zacks reports. Six analysts have made estimates for Ionis Pharmaceuticals’ earnings. The lowest EPS estimate is $0.88 and the highest is $1.39. Ionis Pharmaceuticals posted earnings per share of $2.42 during the same quarter last year, which would indicate a negative year over year growth rate of 50.4%. The company is scheduled to announce its next quarterly earnings report on Wednesday, February 26th.
On average, analysts expect that Ionis Pharmaceuticals will report full-year earnings of $1.99 per share for the current financial year, with EPS estimates ranging from $1.60 to $2.17. For the next financial year, analysts forecast that the business will report earnings of $0.21 per share, with EPS estimates ranging from ($1.43) to $1.08. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, November 6th. The company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.49. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The company had revenue of $168.00 million during the quarter, compared to the consensus estimate of $152.47 million. During the same period in the previous year, the company posted ($0.03) EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year.
In other Ionis Pharmaceuticals news, CFO Elizabeth L. Hougen sold 4,000 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $58.80, for a total value of $235,200.00. Following the completion of the transaction, the chief financial officer now directly owns 24,055 shares of the company’s stock, valued at approximately $1,414,434. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director now directly owns 13,495 shares of the company’s stock, valued at $809,700. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,776 shares of company stock valued at $701,818. 2.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Benjamin F. Edwards & Company Inc. acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at $125,000. Creative Planning grew its holdings in Ionis Pharmaceuticals by 2.4% during the 3rd quarter. Creative Planning now owns 23,285 shares of the company’s stock worth $1,395,000 after acquiring an additional 552 shares in the last quarter. IFM Investors Pty Ltd grew its holdings in Ionis Pharmaceuticals by 46.0% during the 3rd quarter. IFM Investors Pty Ltd now owns 12,234 shares of the company’s stock worth $733,000 after acquiring an additional 3,854 shares in the last quarter. California Public Employees Retirement System grew its holdings in Ionis Pharmaceuticals by 34.1% during the 3rd quarter. California Public Employees Retirement System now owns 291,371 shares of the company’s stock worth $17,456,000 after acquiring an additional 74,015 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Ionis Pharmaceuticals by 7.5% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 865,463 shares of the company’s stock worth $51,850,000 after acquiring an additional 60,363 shares in the last quarter. 87.27% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ IONS traded up $0.69 during midday trading on Friday, hitting $60.38. 961,000 shares of the company’s stock were exchanged, compared to its average volume of 1,138,906. The company has a quick ratio of 10.31, a current ratio of 10.39 and a debt-to-equity ratio of 0.44. Ionis Pharmaceuticals has a 12 month low of $48.27 and a 12 month high of $86.58. The company’s 50 day moving average price is $57.45 and its 200 day moving average price is $63.39. The firm has a market capitalization of $8.24 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 2.27 and a beta of 1.90.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
See Also: LIBOR
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.